This was confirmed with cytotoxicity testing in vitro; the lethal dose required to kill 50% (LD50) of CD133+ or CD133- D456MG cells was not significantly different, and D456MG, including the GSCs, were more sensitive to killing by G207 and M002 than six adult GBM xenografts tested (Cassady et al., 2009; Friedman and Gillespie, 2011). The gene discussed is PROM1; the disease is glioblastoma.